

Date: Wednesday, 11th March 2020
Our Ref: MB/SS FOI 4286

Sid Watkins Building
Lower Lane
Fazakerley
Liverpool L9 7BB
Tel: 01515253611
Fax: 01515295500
Direct Line: 01515563038

Re: Freedom of Information Request FOI 4286

We are writing in response to your request submitted under the Freedom of Information Act, received in this office on 09th March 2020.

Your request was as follows:

1. Does the hospital/hospitals treat chronic migraine?

Yes.

2. Total number of unique patients treated in the last 12 months for migraine

I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not collate information as our data sets do not differentiate between migraine and chronic migraine in diagnosis coding. However, Section 16 of the FOIA places a duty on us to provide help and assistance where possible therefore we have provided an overall figure below for all migraine diagnosis:

5036 Migraine Diagnosis for the 12 month period March 2019 to February 2020.

3. Total number of unique chronic migraine patients treated in the last 12 months

I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not collate information as our data sets do not differentiate between migraine and chronic migraine in diagnosis coding. However, Section 16 of the FOIA places a duty on us to provide help and assistance where possible therefore we have provided an overall figure below for all migraine diagnosis:

5036 Migraine Diagnosis for the 12 month period March 2019 to February 2020.

4. Does the trust actively inject chronic migraine patients (as opposed to sending to another hospital for injections)?

Yes.

5. Total number of chronic migraine patients treated in the last 12 months with the following:

- a. Botulinum Toxin (i.e. Botox, Dysport, Xeomin)
- b. Ajovy (Fremanezumab)
- c. Aimovig (Erenumab)

d. Emgality (Galcanezumab)

5.a. Botulinum Toxin (i.e. Botox, Dysport, Xeomin) - I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not collate information for the number of patients treated with botulinum. This is due to it is kept as stock in all areas injected and prescriptions are on paper. Under the FOI Act, we are not required to create this information in order to answer your request. I should explain that the FOI Act is to do with transparency of information held by public authorities. It gives an individual the right to access recorded information held by public authorities. The FOI Act does not require public authorities to generate information, or to answer questions, provide explanations or give opinions, unless this is recorded information that they already hold.

5.b. Ajoovy (Fremanezumab) - I confirm that The Walton Centre NHS Foundation Trust holds the information you have requested. However, I am unable to provide you with that information as I consider that the following exemptions apply to it: Section 40 (2) - Third Party Data

This information is exempt from disclosure under Section 40(2) of the Freedom of Information Act 2000 (FOIA), due to the minimal number of patients identified, in answering your query may lead to the undue stress of families and patients as this information may still lead to patients being identified. Therefore this information has not been released for reasons of confidentiality.

This exemption is not subject to the public interest test.

This response therefore acts as a refusal notice under section 17 of the FOIA.

5.c. Aimovig (Erenumab) - 32 patients

5.d. Emgality (Galcanezumab) - 0 patients

Please see our response above in [blue](#).

Re-Use of Public Sector Information

All information supplied by the Trust in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2005, Statutory Instrument 2005 No. 1515 which came into effect on 1st July 2005.

Under the terms of the Regulations, the Trust will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however the Trust reserves the right, in certain circumstances, to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information can be found at www.opsi.gov.uk where a sample license terms and fees can be found with guidance on copyright and publishing notes and a Guide to Best Practice and regulated advice and case studies, at www.opsi.gov.uk/advice/psi-regulations/index.htm

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to the Freedom of Information Office at the address above.

Please remember to quote the reference number, FOI 4286 in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioners Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

Yours sincerely

Mike Burns

Mr. Mike Burns, Executive Lead for Freedom of Information